Stockscreener 앱 받기
21.95
1.81%
0.39
시장 영업 전:
21.85
-0.10
-0.46%
전일 마감가:
$21.56
열려 있는:
$21.51
하루 거래량:
386.23K
Relative Volume:
0.73
시가총액:
$1.44B
수익:
-
순이익/손실:
$-137.95M
주가수익비율:
-8.7013
EPS:
-2.5226
순현금흐름:
$-107.11M
1주 성능:
+6.76%
1개월 성능:
+8.50%
6개월 성능:
+20.94%
1년 성능:
+119.50%
1일 변동 폭
$20.78
$22.30
1주일 범위
$19.93
$22.30
52주 변동 폭
$8.48
$24.25
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
21.95 | 1.42B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 개시 | BofA Securities | Buy |
| 2026-01-29 | 개시 | Citizens JMP | Mkt Perform |
| 2026-01-08 | 개시 | BTIG Research | Buy |
| 2025-12-18 | 개시 | Mizuho | Neutral |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? - AOL.com
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? - The Motley Fool
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics (BCAX) director receives 19,475-share option tied to RA Capital - Stock Titan
[8-K] Bicara Therapeutics Inc. Reports Material Event - Stock Titan
Bicara Therapeutics Inc. presents three year Phase 1b results for ficerafusp alfa combination in HPV negative HNSCC - Traders Union
BCAX News | BICARA THERAPEUTICS INC (NASDAQ:BCAX) - ChartMill
BCAX Stock Price, Quote & Chart | BICARA THERAPEUTICS INC (NASDAQ:BCAX) - ChartMill
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating By Investing.com - Investing.com India
Bicara (BCAX) Q4 2025 Earnings Transcript - AOL.com
Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data - TipRanks
Bicara Therapeutics Inc. presents breakthrough in EGFR-targeted therapy for HPV-negative HNSCC - Traders Union
Bicara Therapeutics CFO Ivan Hyep sells $187,883 in stock By Investing.com - Investing.com India
Bicara Therapeutics CFO Ivan Hyep sells $187,883 in stock - Investing.com
BCAX (Nasdaq: BCAX) insider notice: 5,500 shares tied to option exercise - Stock Titan
Bicara Therapeutics Inc. launches FORTIFI clinical trial targeting 1L R/M HPV negative HNSCC patients - Traders Union
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
BCAX: Ficera doubled three-year survival and achieved deep, durable responses in HPV-negative head and neck cancer - TradingView
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer - TradingView
BCAX: Ficerafusp alfa delivers deep, durable responses and doubles three-year survival in HPV-negative head and neck cancer - TradingView
BCAX: FICERA plus pembrolizumab delivers deep, durable responses and extended survival in HPV-negative HNSCC - TradingView
Bicara Therapeutics Reports Positive Three-Year Survival Data for Ficerafusp Alfa Plus Pembrolizumab in 1L R/M HPV-Negative HNSCC - Minichart
Bicara reports three-year survival data for cancer therapy By Investing.com - Investing.com South Africa
Bicara reports three-year survival data for cancer therapy - Investing.com
Bicara Therapeutics Reports Promising Three-Year Follow-Up Data for Ficerafusp Alfa in Combination with Pembrolizumab in HPV-Negative Head and Neck Cancer - Quiver Quantitative
Bicara Therapeutics: 1500mg Ficerafusp Alfa + Pembrolizumab Shows Estimated 31% 3‑Year OS in 1L R/M HPV‑Negative HNSCC - TradingView
New data from Bicara Therapeutics Inc. reveals long term outcomes from HPV negative HNSCC trial - Traders Union
Ficerafusp Alfa Plus Pembrolizumab Demonstrated - GlobeNewswire
Bicara Therapeutics (BCAX) CEO sells 15K shares and exercises options - Stock Titan
Bicara Therapeutics Highlights Momentum in Earnings Call - TipRanks
A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback - Yahoo Finance
Bicara Therapeutics’ Earnings Call Highlights Ficera Momentum - TipRanks
Bicara Therapeutics president & COO Ryan Cohlhepp sells $253k stock - Investing.com
Bicara Therapeutics president & COO Ryan Cohlhepp sells $253k stock By Investing.com - Investing.com South Africa
Bicara Therapeutics Inc (BCAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bicara Therapeutics Inc 주식 (BCAX) 내부자 거래
1.27%
1.43%
자본화:
|
볼륨(24시간):